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Iron deficiency remains the largest nutritional deficiency worldwide and the main cause of
anaemia. Severe iron deficiency leads to anaemia known as iron deficiency anaemia
(IDA), which affects a total of 1·24 billion people, the majority of whom are children and
women from resource-poor countries. In sub-Saharan Africa, iron deficiency is frequently
exacerbated by concomitant parasitic and bacterial infections and contributes to over
120 000 maternal deaths a year, while it irreparably limits the cognitive development of chil-
dren and leads to poor outcomes in pregnancy.
Currently available iron compounds are cheap and readily available, but constitute a non-
physiological approach to providing iron that leads to significant side effects. Consequently,
iron deficiency and IDA remain without an effective treatment, particularly in populations
with high burden of infectious diseases. So far, despite considerable investment in the past 25
years in nutrition interventions with iron supplementation and fortification, we have been
unable to significantly decrease the burden of this disease in resource-poor countries.
If we are to eliminate this condition in the future, it is imperative to look beyond the strat-
egies used until now and we should make an effort to combine community engagement and
social science approaches to optimise supplementation and fortification programmes.
Iron deficiency: Iron deficiency anaemia: Capacity building: Iron supplementation
Iron deficiency anaemia: the scale of the problem
Iron deficiency remains the most prevalent nutritional
deficiency worldwide, affecting an estimated 4–6 billion
people. Iron deficiency is also the main cause of anaemia
in children and women in both high or low infection bur-
den settings(1,2). Two billion people, about 30 % of the
world’s population, and 43 % of children between the
age 6–59 months, are anaemic and the prevalence of
anaemia is five times higher in low- and middle-income
countries (LMIC) than in high-income countries(3,4). As
such, iron deficiency anaemia (IDA) is the largest nutri-
tional deficiency disorder in the world and one of the
five leading causes of global disease burden(3). At any
given moment, more individuals suffer from IDA than
any other health problem with a staggering 1·24 billion
affected individuals worldwide(3) (see Fig. 1).
Iron deficiency is associated with multiple pathologies,
including anaemia and defective organ function and for-
mation(5). Iron deficiency in the absence of anaemia is
somewhat subtler in its manifestations than other micro-
nutrient deficiencies, despite being a major contributor to
ill health, premature death and lost earnings in develop-
ing countries. Even mild iron deficiency appears to
impair intellectual development in young children and
is lowering national intelligence quotients(6–10), while
overt IDA is associated with an increased risk of serious
morbidity, poor motor and mental development in
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children, reduced work capacity in adults, poor preg-
nancy outcomes and impaired immunity: all of which
make it one of the most expensive diseases in the world
according to the WHO, causing an estimated 4·05 % of
lost gross domestic product globally(11). For WHO, redu-
cing the prevalence of IDA is one of its six priorities, and
it is estimated that appropriate treatment of IDA not
only could restore individual’s health, but also raise
national productivity levels by as much as 20 %(11–14).
Nevertheless, in the past 25 years, not much has chan-
ged in LMIC, where IDA maintains its top position as
the leading cause of years lived with disability(3), and is
responsible for over 50 000 deaths annually(15), with
iron deficiency contributing to 120 000 maternal deaths
per year(16). This is perhaps not surprising, since elimin-
ating IDA in these countries is particularly challenging
due to the double burden of IDA and infectious diseases,
and malaria, HIV/AIDS, tuberculosis, hookworm and
other intestinal parasitic or bacterial infections, all con-
tribute to the anaemia burden.
Iron deficiency in the UK
Recently, Public Health England and the Food Stan-
dards Agency has published the combined results from
years 7 and 8 (2014/2015–2015/2016) of the National
Diet and Nutrition Survey(17), providing an update on
results from years 5 and 6 published in 2016. Data on
dietary iron intake as well as on biochemical body iron
status indicated an increased risk of iron deficiency in
girls aged 11–18 years and women aged 19–64 years.
When the dietary iron intake was compared with govern-
ment recommendations, the National Diet and Nutrition
Survey reported that 54 % of girls and 27 % of women
had iron intakes below the lower reference nutrient
intake, which is considered inadequate for most indivi-
duals, as it represents the level of intake that is likely
to be sufficient to meet the needs of only 2·5 % of the
population. Interestingly, the proportion of children
aged 1·5–3 years with dietary iron intake below the
lower reference nutrient intake was greater than in the
previous report (10 % compared with 6 % in the
past)(17,18).
Analysis of blood samples of 704 adults and 329 chil-
dren in the same UK survey provided evidence of IDA
(as indicated by low Hb levels) and low iron stores
(plasma ferritin) in all age/sex groups in the population,
with a higher prevalence in females. Based on the WHO
criteria for the definition of iron deficiency and anaemia,
the prevalence of IDA in the UK was 9 % for girls aged
11–18 years (v. 5 % in the previous report), while low
iron stores were evident in 24 % of adolescent girls, 5
% of adult women and 1 % of older women(17). It is
important to note that pregnant or breast-feeding
women who may have different requirements were
among the population groups that were excluded from
the survey.
These data support that iron deficiency, and IDA,
remain impactful nutritional deficiency disorders in the
UK, despite the wide-ranging availability of fortified
foods and iron supplements.
Strategies to prevent and treat iron deficiency
The most commonly used strategies to control iron
deficiency are supplementation (including multi-micro-
nutrient powders), food fortification, dietary diversifica-
tion and control of parasitic and other infections.
Supplementation or fortification programmes are often
the selected short-term approaches because they are cost-
effective and relatively easy to implement.
The current WHO recommendation for the prevention
of IDA is for daily iron supplementation for 3 consecu-
tive months in a year to all pre-menopausal women, ado-
lescent girls and young children in countries with over
40 % anaemia prevalence (i.e. the majority of countries
in sub-Saharan Africa and South East Asia) and
intermitted supplementation in settings with lower
prevalence(19,20).
Iron compounds are widely available but typically
generate a non-physiological bolus of bio-accessible
and reactive ionic iron that can cause significant adverse
effects, either in the colon (i.e. unabsorbed iron fraction)
or in circulation (i.e. absorbed iron fraction)(21–24).
Meta-analysis of trials involving nearly 10 000 young
children in developing countries have consistently
shown that conventional soluble oral iron supplementa-
tion used to treat IDA is associated with increased infec-
tion including bloody diarrhoea(22,25–27) and detrimental
changes to the gut microbiome and gut inflamma-
tion(27,28), further increasing the burden from enteric
infection and environmental enteropathy (i.e. persistent
gut damage and inflammation that leads to malabsorp-
tion), which is a major cause of growth failure in children
in resource-poor environments(29,30). Wide-scale home
fortification programmes hold promise for reaching
at-risk populations with the use of multi-micronutrient
powders(31). Nonetheless, progress has been painstak-
ingly slow, in spite of the dimension of the problem,
and strategies to control iron deficiency have failed to
decrease the global burden of this deficiency. This is par-
ticularly the case for young children in sub-Saharan
Africa, where iron supplementation has consistently
shown limited efficacy and a potential for increasing
infection risk(21,26,32).
Fig. 1. Prevalence of iron deficiency, iron deficiency anaemia (IDA)
and anaemia worldwide. Adapted from(3).
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Our biggest challenge: iron bioavailability in
high-infection settings
Infection
Many LMIC have high prevalence of malnutrition and
infection, both of which contribute to a vicious
cycle(33). First, malnutrition weakens barrier and
immune functions, allowing pathogens easier access
and overall impairing the host’s ability to fight patho-
gens(34). Secondly, damage to the intestinal mucosa lin-
ing caused by enteric infection and inflammation will
decrease nutrient status due to impaired absorption and
diarrhoea; therefore predisposing to further infection
and worsening nutritional status, and perpetuating a
cycle of chronic infection and malnutrition(34). This
cycle of infection, malnutrition and persistent inflamma-
tion will lead to malabsorption and in the long term to
growth failure and mortality(34–36).
The state of chronic infection leads to high levels of
hepcidin and anaemia. Elevated hepcidin can decrease
iron absorption, irrespective of the iron source, and
also leads to low circulating serum iron and transferrin
saturation (hypoferraemia), through the mobilisation of
circulating iron to the iron stores in macrophages and
the liver(37–40).
Conversely, iron supplementation regimens can cause
the release of a high bolus of iron in the blood, which
may transiently overwhelm transferrin’s iron binding
capacity and generate redox-reactive non-transferrin-
bound iron, which could be available to extra-cellular
pathogenic organisms causing infection(41–45). Indeed, a
committee chaperoned by the WHO concluded that
these non-physiological high doses of highly absorbable
iron may bypass the naturally evolved systems that safely
chaperone iron and be the cause of the excess non-trans-
ferrin-bound iron, therefore causing the afore-mentioned
harmful effects(46). This conclusion, supported by a
recent study, has shown that 3 h after consumption of a
standard iron supplement dose, human serum greatly
supports enhanced rates of replication of pathogenic
bacteria(47).
Nutritional immunity
Iron is an essential nutrient to virtually all human patho-
gens, and the most virulent and invasive strains are those
with multiple iron acquisition and utilisation mechan-
isms(48–51). Furthermore, iron can also regulate evolu-
tionary transitions between commensal and pathogenic
states in microbes(52). Nutritional immunity is an innate
defence mechanism characterised by the sequestration
of iron and other essential trace elements from the circu-
lation to reduce iron availability and limit pathogen
growth and virulence(34,53,54).
There is a constant competition for iron between the
human host and invasive pathogens(39). Anaemia is pro-
tective against malaria and iron supplementation
removes this protective effect(55,56). Iron supplementation
may also increase the risk of respiratory infections and
other systemic infections, due to iron’s ability to increase
virulence and multiplication of pathogens(47,57,58). Our
body has evolved very effective ways to intentionally
reduce circulating iron when challenged by infection in
an attempt to ‘starve’ the pathogen. Central to
nutritional immunity are high-affinity iron transport pro-
teins, such as transferrin and lactoferrin, which allow us
to ‘starve’ pathogens by maintaining free iron atoms
scarce at concentrations of 10−18 M(54,59,60). As aforemen-
tioned, a key aspect of our response to infection is the
more recently discovered hormone hepcidin, the master
regulator of body iron homeostasis, which allows our
body to reduce circulating iron by supressing intestinal
iron absorption and decreasing its release from body
iron stores. Any iron supplementation regimen that
aims to be effective in a high-infection burden setting
needs to acknowledge the close interaction between
iron and infection and this key aspect of our natural
immunity cannot be overlooked.
Hepcidin/inflammation
Our body has no means of excreting excess iron and the
control of body iron levels occurs by regulation of iron
absorption. Absorption of iron from the gastrointestinal
tract is tightly regulated by the systemic need for iron
through the action of the hormone hepcidin(39,61,62).
Hepcidin responds to changes in body iron stores, tissue
hypoxia and demand for iron, and it alters absorption
accordingly. Hepcidin, as the master regulator of iron
homeostasis, is the main inhibitor of iron export from
cells (including enterocytes, hepatocytes and macro-
phages) into blood circulation(5). When hepcidin is ele-
vated, it binds to ferroportin (the only cellular iron
exporter known) and it causes its internalisation and deg-
radation, so that cellular iron is locked inside cells and
cannot (1) be absorbed into the bloodstream or (2) be
released from body iron stores(63,64).
In IDA, hepcidin levels tend to be low to allow iron
absorption, but in the presence of inflammation or in
iron-replete individuals, hepcidin levels are usually
high(38,65,66). Anaemia of inflammation, also called
anaemia of chronic disease, is characterised by high hep-
cidin, high iron stores and low circulation iron(67).
In anaemia of inflammation, when hepcidin levels are
high, if non-physiological bolus doses of highly absorb-
able iron supplements are initiated, this iron will be
poorly absorbed, while unabsorbed iron will just be
excreted in the stools(66). Iron absorption can be as
high as 50 % when hepcidin is switched off and is virtu-
ally zero when hepcidin is high(66).
Microbiome
Low ‘free’ iron availability in the colon is a major modu-
lator of our gut microbiome particularly in early life or
disease. Both iron deficiency and iron supplementation
have an impact on the gut microbiome(68,69). The estab-
lishment of an adult-like microbiome requires
bio-accessible iron to maintain diversity(69,70), but in cer-
tain population groups, iron supplementation could
cause or contribute to microbiome dysbiosis (see Fig. 2).
Excess unabsorbed dietary iron through fortification
or supplementation can modify the gut microbiota
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equilibrium and favour the growth of pathogenic strains
over barrier strains. Iron is essential for the virulence and
colonisation of most enteropathogenic strains(71–74).
However, gut bacteria species considered most beneficial
to the host, i.e. barrier function bacteria such as members
of the Lactobacillacae and Bifidobacteriacae families,
have either no or a very low requirement for iron(75,76).
Indeed, studies in children have shown the detrimental
effects of currently used soluble forms of iron on the
gut microbiome, suggesting that iron supplements
decrease the abundance of beneficial bacteria groups
such as Lactobacillus and Bifidobacterium and increase
the relative abundance of potential enteropathogenic
bacteria belonging to the Enterobacteriaceae family,
and also increase intestinal inflammation(27,28,76). This
gut microbiome dysbiosis combined with mucosal
inflammation can lead to reduced resistance to infection,
an increase in the risk of diarrhoea and an increase in gut
permeability leading to endotoxaemia(22,27,76–79). In this
way, current iron supplementation could be contributing
to the vicious cycle of infection, diarrhoea and eventually
causing further anaemia. Use of prebiotics together with
iron supplements may be able to alleviate part of the
gut-related adverse effects of the iron supplements, but
further studies are needed(76).
Future outlook: science and beyond
Micronutrient nutrition is a key aspect of the inter-
national development agenda and is integral to the UN
sustainable development goals. Recognising the import-
ance of micronutrient nutrition is also paramount in
defining strategies to address the double burden of under-
nutrition and overnutrition and the double burden of
malnutrition and infection, both widely prevalent across
most countries in the world. The WHO recently recog-
nised that a considerable investment in building public
health nutrition capacity is required, particularly in
LMIC, alongside a persistent effort in obtaining scientific
evidence for the effectiveness of existing and new nutri-
tion programmes and interventions(80). Additionally,
obtaining scientific evidence through clinical trials and
nutrition intervention studies in ‘virgin’ rural settings in
LMIC also carries the ethical responsibility to add social
value, with community engagement and capacity build-
ing, which goes beyond the scientific discovery.
Traditionally, research communication has been reserved
for scientific publications and news pieces in research
websites. However, this strategy creates a science isola-
tion that is not effective in today’s world. Therefore,
we must train researchers not only in their ability to con-
duct nutrition science research but also in their ability to
communicate science to the wider community and gen-
eral public. Equally we must equip public health profes-
sionals, nurses and clinicians in LMIC in their ability to
engage with the local communities as much as in their
knowledge of how to manage the prevention and treat-
ment of various forms of malnutrition. A practical
example of how we can combine scientific discovery, cap-
acity building and community engagement is outlined
later with the IHAT-GUT iron supplementation clinical
trial in The Gambia.
Case study: IHAT-GUT trial in The Gambia
Since iron delivered naturally through foods may be a
safer alternative(5), there is a growing interest in develop-
ing novel nano iron compounds or delivery systems to
use in fortification and supplementation(81–84). One of
the strategies proposed is to use a mimetic of the iron
core of ferritin, namely iron hydroxide adipate tartrate
(IHAT), to alleviate the adverse effects associated with
reactive ionic iron(85). The hypothesis is that supplemen-
tation with IHAT will cause a slow release of iron into
the blood, a lower rise of transferrin saturation, resem-
bling that of natural food iron(85–87), and may constitute
a safer option for supplementation, particularly in popu-
lation settings with high-infection burden. Pre-clinical
data indicate that IHAT does not accumulate in the
intestinal mucosa and can promote a beneficial micro-
biota after dysbiosis(85,87). IHAT and standard-of-care
ferrous sulphate, are currently being tested in a rando-
mised placebo-controlled double-blind clinical trial tak-
ing place at the MRC Unit The Gambia at the London
School of Hygiene & Tropical Medicine. The
IHAT-GUT trial (NCT02941081) is enrolling about
700 young children living in some of the poorest and
more rural communities in The Gambia, where risk of
infection and diarrhoea are very high.
As add-on projects to the IHAT-GUT trial, we have
conducted nutrition training workshops and we are
also conducting a social science project, where we docu-
ment the ‘ins’ and ‘outs’ of setting up a nutrition inter-
vention clinical trial, aimed at translating novel
chemistry into public benefit, in a rural setting in The
Gambia (see Fig. 3). We believe this social science aspect
of research training is as important to global health and
nutrition science researchers as the training in nutrition
science itself. The social science project is gathering the
personal views from clinical and field study staff, all of
whom where based in The Gambia before the trial com-
menced, and will, hopefully, demonstrate that it is
Fig. 2. Model of microbiome dysbiosis caused by an excess of
bio-accessible iron (Fe) in the colon.
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possible to translate international science to rural Africa
and that it is possible to conduct nutrition clinical trials
in these rural settings to ICH-GCP international stan-
dards. Likewise, it will illustrate the many challenges
faced by the researchers, for example, how to implement
clinical studies in new settings, how to attract motivated
and skilled staff, etc. This project will help staff and com-
munities to embrace these studies and to acknowledge
the added value of being part of nutrition research. We
envisage that such information will inspire the next gen-
eration of researchers in global health and international
nutrition, from academia or industry, to translate more
international science to rural resource-poor settings.
Conclusion
Anaemia is multifactorial as it is caused by both poor
diet and high levels of infection and inflammation.
Nowhere more than in sub-Saharan Africa do these
causes coexist, and eliminating iron deficiency and
anaemia in African children and women still remains
one of the main nutritional challenges of the twenty-first
century. Iron supplementation in malaria-endemic areas
or in regions with high-infection burden needs to be
implemented with caution, should target those who are
anaemic or at a high risk of deficiency, and be accompan-
ied by strategies to prevent and treat malaria, hookworm,
schistosomiasis and other nutrient deficiencies, such as
vitamin B12, folate and vitamin A
(32,46).
In spite of many successes, it is clear that more needs to
be done to eliminate iron deficiency in LMIC. Today, pub-
lic health interventions that can correct or prevent iron and
other micronutrient deficiencies merit the highest priority
for national and international organisations. Routine
monitoring for compliance, research into the best delivery
vehicles, ensuring the continuous availability of supple-
ments or fortified foods at the community level, engaging
local community and community leaders, and capacity
building are the key factors for sustaining achievements
and increasing the success of such programmes. Only
then will we fully value the World Bank comment: ‘the
control of vitamin and mineral deficiencies is one of the
most extraordinary development-based scientific advances
of recent years. Probably no other technology available
today offers as large an opportunity to improve lives and
accelerate development at such low cost in such short time.’
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